Liquid biopsies to classify lung graft damage (LEONARDO)
Official title: Liquid Biopsies for Lung Allograft Damage Classification
Run by Vastra Gotaland Region · NCT06679257 · Data updated 2026-11-12
This study will test whether a blood-based PCR cell-free DNA test combined with other markers can quickly distinguish rejection, infection, and other types of lung transplant graft damage in people who have had a lung transplant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 146 (estimated) |
| Sponsor | Vastra Gotaland Region Government |
| Locations | 1 site (Gothenburg, Västra Götaland County) |
| Status | Recruiting |
| Started | November 15, 2024 |
| Main results expected | December 2029 |
| Study ends | December 2030 |
| Registry record updated | September 16, 2025 |
| Trial ID | NCT06679257 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people who have received a lung transplant and are followed at or can attend Sahlgrenska University Hospital and can read and sign consent in the provided languages.
✕Probably not a fit
People who are not lung transplant recipients, who are not followed at or cannot attend the participating centre, or who cannot read and sign consent in the provided languages are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-centre prospective observational cohort of lung transplant recipients followed at Sahlgrenska University Hospital. Blood will be drawn at fixed follow-up visits and at clinical events, and an in-house PCR-based cell-free DNA (cfDNA) assay will be combined with specific additional biomarkers to identify the type of allograft damage. Every sampling will be paired with the current clinical gold-standard diagnostics, and all biomarker analyses will be performed blinded at a separate laboratory. Control samples will consist of time points without detected allograft damage.
Why it matters
Potential benefit: If successful, the test could allow faster and more accurate detection of rejection or infection after lung transplant, enabling earlier targeted treatment and potentially improving long-term outcomes.
How similar studies have gone: Donor-derived cfDNA approaches have shown promise in other organ transplants and preliminary lung transplant work, but a direct-to-clinic PCR cfDNA method remains relatively new and is still being validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Luing Transplanted and followed up within the reach of the study paricipating centres. A good understanding to read and write within the languages in which the consent is provided. Exclusion Criteria: * Not Lung Transplanted or not followed up within the reach of the study paricipating centres. No good understanding to read and write within the languages in which the consent is provided.
Where it's running
-
Sahlgrenska University hospital
Gothenburg, Västra Götaland County, Sweden Recruiting
Study contacts
- Study coordinator: Jesper M Magnusson, MD, PhD
- Email: jesper.magnusson@gu.se
- Phone: +0463421000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers for Response to ECP in Lung Transplant Patients with CLAD
This study tests early biomarkers from blood and MRI to see if extracorporeal photopheresis helps lung transplant patients with chronic lung allograft dysfunction.
-
Identifying biomarkers for lung transplant dysfunction
This study is trying to find specific markers in the body that can help doctors understand and manage problems after lung transplants for patients at Foch Hospital.
-
Surfactant delivery methods in preterm infants with RDS in Sweden
This study tests different ways of giving surfactant to preterm babies with respiratory distress to see which method works best when care is routine.
-
Home-based Acute Care for Older Adults Initiated by Emergency Services
A team-based, home-delivered acute care approach for people 75+ is being studied to see if it can match the results of usual ED care in terms of care needs and mortality.
-
Accelerated iTBS for Depression in routine care
This study tests whether an accelerated iTBS treatment can help people with depression when used in regular clinical practice.
-
Postpartum pelvic floor recovery and early rehabilitation after vaginal birth
This project tests whether early, individualized pelvic floor muscle training starting 2–3 weeks after a vaginal birth helps people with postpartum pelvic floor symptoms recover better than usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.